A drug accelerator that partners the creative power of academic scientists with drug discovery professionals to consistently advance groundbreaking biological discoveries towards patients in need would be transformational. One such model, the Tri-Institutional Therapeutics Discovery Institute, evolved a series of best practices for identifying, selecting, executing, and completing academic-initiated drug discovery projects, as evidenced by licensing successes, is described.
